

Shibin Zhou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8110510/publications.pdf>

Version: 2024-02-01

34
papers

24,154
citations

236612

25
h-index

360668

35
g-index

37
all docs

37
docs citations

37
times ranked

35757
citing authors

#	ARTICLE	IF	CITATIONS
1	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. <i>New England Journal of Medicine</i> , 2015, 372, 2509-2520.	13.9	7,696
2	Cancer Genome Landscapes. <i>Science</i> , 2013, 339, 1546-1558.	6.0	6,507
3	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. <i>Science</i> , 2017, 357, 409-413.	6.0	4,945
4	Detection and localization of surgically resectable cancers with a multi-analyte blood test. <i>Science</i> , 2018, 359, 926-930.	6.0	1,872
5	Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 11774-11779.	3.3	578
6	Tumour-targeting bacteria engineered to fight cancer. <i>Nature Reviews Cancer</i> , 2018, 18, 727-743.	12.8	439
7	Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. <i>Science</i> , 2020, 369, .	6.0	351
8	Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. <i>Nature</i> , 2021, 596, 126-132.	13.7	234
9	Targeting a neoantigen derived from a common <i>TP53</i> mutation. <i>Science</i> , 2021, 371, .	6.0	194
10	Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. <i>Nature</i> , 2018, 564, 273-277.	13.7	193
11	Applications of liquid biopsies for cancer. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	151
12	Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy. <i>ACS Nano</i> , 2015, 9, 6861-6871.	7.3	119
13	Preventing cytokine storm syndrome in COVID-19 using β -1 adrenergic receptor antagonists. <i>Journal of Clinical Investigation</i> , 2020, 130, 3345-3347.	3.9	107
14	Bispecific antibodies targeting mutant <i>RAS</i> neoantigens. <i>Science Immunology</i> , 2021, 6, .	5.6	106
15	Targeting public neoantigens for cancer immunotherapy. <i>Nature Cancer</i> , 2021, 2, 487-497.	5.7	79
16	Functional characterization of CD4+ T cell receptors crossreactive for SARS-CoV-2 and endemic coronaviruses. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	72
17	<i>Clostridium novyi</i> -NT can cause regression of orthotopically implanted glioblastomas in rats. <i>Oncotarget</i> , 2015, 6, 5536-5546.	0.8	65
18	A diaCEST MRI approach for monitoring liposomal accumulation in tumors. <i>Journal of Controlled Release</i> , 2014, 180, 51-59.	4.8	52

#	ARTICLE	IF	CITATIONS
19	CEST theranostics: label-free MR imaging of anticancer drugs. <i>Oncotarget</i> , 2016, 7, 6369-6378.	0.8	49
20	Generation of MANAbodies specific to HLA-restricted epitopes encoded by somatically mutated genes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 9967-9972.	3.3	41
21	Direct Detection and Quantification of Neoantigens. <i>Cancer Immunology Research</i> , 2019, 7, 1748-1754.	1.6	40
22	A Robust Approach to Enhance Tumor-selective Accumulation of Nanoparticles. <i>Oncotarget</i> , 2011, 2, 59-68.	0.8	40
23	Targeting loss of heterozygosity for cancer-specific immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	39
24	Characterization of tumor vascular permeability using natural dextrans and CEST MRI. <i>Magnetic Resonance in Medicine</i> , 2018, 79, 1001-1009.	1.9	33
25	TCR \hat{I}^2 chain-directed bispecific antibodies for the treatment of T cell cancers. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	30
26	CT and CEST MRI bimodal imaging of the intratumoral distribution of iodinated liposomes. <i>Quantitative Imaging in Medicine and Surgery</i> , 2019, 9, 1579-1591.	1.1	24
27	Alpha-1 adrenergic receptor antagonists to prevent hyperinflammation and death from lower respiratory tract infection. <i>ELife</i> , 2021, 10, .	2.8	21
28	CEST MRI monitoring of tumor response to vascular disrupting therapy using high molecular weight dextrans. <i>Magnetic Resonance in Medicine</i> , 2019, 82, 1471-1479.	1.9	18
29	Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens. <i>Nature Communications</i> , 2021, 12, 5271.	5.8	17
30	An engineered antibody fragment targeting mutant \hat{I}^2 -catenin via major histocompatibility complex I neoantigen presentation. <i>Journal of Biological Chemistry</i> , 2019, 294, 19322-19334.	1.6	15
31	TCR-mimic bispecific antibodies to target the HIV-1 reservoir. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2123406119.	3.3	10
32	Combination therapy with bacteria and angiogenesis inhibitors: Strangling cancer without mercy. <i>Cancer Biology and Therapy</i> , 2005, 4, 846-847.	1.5	4
33	Combination bacteriolytic cancer therapy: Attacking cancer from inside out. <i>Discovery Medicine</i> , 2004, 4, 33-7.	0.5	2
34	An isogenic cell line panel for sequence-based screening of targeted anticancer drugs. <i>IScience</i> , 2022, 25, 104437.	1.9	2